From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 11 May

Sophia Mavridis
May 11, 2021

Morning Bell 10 May

Jessica Amir
May 10, 2021

Weekly Wrap 7 May

Jessica Amir
May 7, 2021

Morning Bell 7 May

Sophia Mavridis
May 7, 2021

Morning Bell 6 May

Paulina Peters
May 6, 2021

Morning Bell 5 May

Jessica Amir
May 5, 2021

Morning Bell 4 May

Jessica Amir
May 4, 2021

Morning Bell 3 May

Jessica Amir
May 3, 2021

Weekly Wrap 30 April

Jessica Amir
April 30, 2021

Morning Bell 30 April

Sophia Mavridis
April 30, 2021

Morning Bell 29 April

Paulina Peters
April 29, 2021

Morning Bell 28 April

Jessica Amir
April 28, 2021